T.Rx Capital Launches $77.5M Fund I to Invest in Bold Startups at the Intersection of Technology and Biology
T.Rx Capital, a new venture capital firm focused on early-stage healthcare innovation, today announced the close of its inaugural fund, T.Rx Capital Fund I, at $77.5 million. The fund is dedicated to backing visionary founders building at the intersection of technology and biology including biotechnology, techbio, and tech-enabled services.
